Antibodies detected by solid phase anticardiolipin immunoassays are heterogeneous but understanding the nature of this heterogeneity has proven difficult. Differences in any of the following features may account for differences in anticardiolipin antibodies: avidity for cardiolipin, phospholipid cross-reactivity, specificity for β2 glycoprotein I (β2GPI)-cardiolipin complexes, functional activity (as defined by the ability to inhibit phospholipid dependent coagulation reactions) and specificities for different conformations of phospholipids. Understanding these differences may be important in explaining the variations in clinical presentation of patients with these antibodies. This review attempts to define and discuss anticardiolipin heterogeneity.
Harris EN, Gharavi AE, Patel S. et al. Evaluation of the anticardiolipin antibody test: report of an international workshop held 4 April 1986. Clin Exp Immunol1987; 68: 215-22.
3.
Gharavi AE, Harris EN, Asherson RA, Hughes Grv.Anticardiolipin antibody isotype distribution and phospholipid specificity . Ann Rheum Dis1987; 46: 1-6.
4.
Harris EN, Pierangeli S., Birch D.Anticardiolipin wet workshop report: Fifth International Symposium on antiphospholipid antibodies. Am J Clin Pathol1994; 101: 616-24.
5.
Costello PB, Green FABinding affinity of serum immunoglobulin G to cardiolipin and other phospholipids in patients with systemic lupus erythematosus and syphilis. Infect Immun1988; 56: 1738-42.
6.
Levy RA, Gharavi AE, Samaritano LR et al. Characteristics of IgG antiphospholipid antibodies in patients with systemic lupus erythematosus and syphilis. J Rheumatol1990 ; 17: 1036-41.
7.
Qamar T., Levy R., Sammaritano LR et al. Characteristics of high titer aPL in women with and without fetal death. Arthritis Rheum1990; 33: 501-4.
8.
Harris EN, Gharavi AE, Wasley GD et al. Use of an enzyme-linked immunosorbent assay and of inhibition studies to distinguish between antibodies to cardiolipin from patients with syphilis or autoimmune disorders. J Infect Dis1988; 157: 23-31.
9.
Rote NS, Dostal-Johnson D., Branch WDAntiphospholipid antibodies and recurrent pregnancy loss: correlation between the activated partial thromboplastin time and antibodies against phosphatidylserine and cardiolipin. Am J Obstet Gynecol1990; 163: 575-84.
10.
Galli M., Comfurius P., Maasen C. et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet1990 ; 336: 1544-7.
11.
Galli M., Comfurius P., Barbui T. et al. Anticoagulant activity of β2-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb Haemostas1992; 68: 297-300.
12.
McNeil HP, Simpson RJ, Chesterman CN et al. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2 glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA1990; 87: 4120-4.
13.
Matsuura E. , Igarashi V., Fujimoto M. et al. Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. J Immunol1992; 148: 3885-91.
14.
Matsuura E. , Igarashi V., Yasuda T. et al. Anticardiolipin antibodies recognize beta (2)-glycoprotein 1 structure altered by interacting with an oxygen modified solid phase surface. J Exp Med1994; 179: 457-62.
15.
Jones JV, James H., Tan MH et al. Antiphospholipid antibodies require β2 glycoprotein 1 (apolipoprotein H) as cofactor. J Rheumatol1992; 48: 484-6.
Pierangeli SS, Harris EN, Davis SA et al. β2 Glycoprotein I enhances cardiolipin binding activity but is not the antigen for antiphospholipid antibodies. Br J Haematol1992; 82: 565-70.
18.
Gharavi AE, Harris EN, Sammaritano LR et al. Do patients with antiphospholipid syndrome have antibodies to β2 glycoprotein 1? J Lab Clin Med1993; 122: 426-31.
19.
Harris EN, Gharavi AE, Tincani A. et al. Affinity purified anticardiolipin and anti-DNA antibodies. J Clin Lab Immunol1985; 17: 155-62.
20.
Pengo V., Heine MJ, Thiagarajan P. et al. Immunological specificity and mechanism of action of IgG lupus anticoagulants. Blood1987; 70: 69-76.
21.
McNeil HP, Chesterman CN, Krilis SABinding specificity of lupus anticoagulants and anticardiolipin antibodies . Thromb Res1988; 52: 609-19.
22.
McNeil HP, Chesterman CN, Krilis SAAnticardiolipin antibodies and lupus anticoagulants comprise separate antibody subgroups with different phospholipid binding characteristics. Br J Haematol1989; 73: 506-10.
23.
Exner T., Shaman N., Trudinger B.Separation of anticardiolipin antibodies from lupus anticoagulation a phospholipid coated polystyrene column. Biochem Biophys Res Commun1988; 155: 1001-7.
24.
Pengo V., Biasiolo A.Purification of anticardiolipin and lupus anticoagulant activities by using cardiolipin immobilized on agarose beads. Thromb Res1993; 72: 423-30.
25.
Goldsmith GH , Pierangeli SS, Branch DW et al. Inhibition of prothrombin activation by antiphospholipid antibodies and β2 glycoprotein I. Br J Haematol (in press).
26.
Rauch J., Tannenbaum M., Tannenbaum H. et al. Human hybridoma lupus anticoagulants distinguish between lamellar and hexagonal phase lipid systems. J Biol Chem1986; 261: 9672-8.
27.
Janoff AD, Rauch J.The structural specificity of antiphospholipid antibodies in autoimmune disease . Chem Phys Lipids1986; 40: 315-22.
28.
Harris EN, Gharavi AE, Loizou S. et al. Cross-reactivity of antiphospholipid antibodies. J Clin Lab Immunol1985; 16: 1-6.
29.
Pierangeli SS, Harris EN, Goldsmith G. et al. Are immunoglobulins with lupus anticoagulant activity specific for phospholipids?Br J Haematol1993; 85: 124-32.
30.
Gharavi A., Lockshin MDEnhancement of antiphospholipid antibody activity by Tween 20. J Immunol Methods1988; 114: 277.
31.
Triplett DA , Brandt JT, Musgrave KA et al. Relationship between lupus anticoagulants and antibodies to phospholipids. JAMA1988 ; 259: 550-4.
32.
Branch DW, Rote NS, Dostal DA et al. The demonstration of lupus anticoagulant by an enzyme-linked immunosorbent assay. Clin Immunol Immunopathol1987; 42: 63-75.
33.
Schousboe I.Binding of β2-glycoprotein I to platelets: effect of adenylate cyclase activity. Thromb Res1980; 19: 225-37.
34.
Nimpf J., Bevers EM, Bomans Phh et al. Prothrombinase activity of human platelets is influenced by β2 glycoprotein I. Biochim Biophys Acta1986; 884: 142-4.
35.
Schousboe I.β2-glycoprotein 1: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood1985; 66: 1086-91.
36.
Keeling DM, Wilson Ajg, Mackie IJ et al. Role of β2-glycoprotein 1 and antiphospholipid antibodies in activation of protein C in vitro. J Clin Pathol1993; 46: 908-11.
37.
Arvieux J., Pouzol P., Roussel B. et al. Measurement of antiphospholipid antibodies by ELISA using β2 glycoprotein 1 as an antigen. Br J Haematol1992; 81: 568-73.
38.
Viard JP, Amoura Z., Bach JFAssociation of anti-β2 glycoprotein with lupus circulating anticoagulant and thrombosis in SLE. Am J Med1992; 93: 181-6.
39.
Allegri F., Balestrieri G., Cattaneo R. et al. The plasma cofactor and anticardiolipin antibodies. Clin Exp Rheumatol1990; 8: 613-17.
40.
Harris EN, Pierangeli S.What is the 'true' antigen for antiphospholipid antibodies. Lancet1990; 336: 1550 (letter).
41.
Wagenacht DW , McIntyre JAChanges in β2-glycoprotein 1 antigenicity induced by phospholipid binding . Thromb Haemostas1993; 69: 361-5.
42.
Gharavi AE, Sammaritano LR, Wen J. et al. Induction of antiphospholipid autoantibodies by immunization with β2 glycoprotein 1. J Clin Invest1992; 90: 1105-9.
43.
Pierangeli SS, Harris ENInduction of phospholipid binding antibodies in mice and rabbits by immunization with human β2 glycoprotein 1 or anticardiolipin antibodies alone. Clin Exp Immunol1993; 93: 269-72.
44.
Veltkamp JJ , Kerkhoven P., Loeliger EACirculating anticoagulant in disseminated lupus erythematosus: proposed mode of action. Haemostasis1974; 2: 253-9.
45.
Feinstein DI , Rapaport SIAcquired inhibitors of blood coagulation . In: Progress in Haemostasis and Thrombosis. Spaet TN (ed). New York: Grune and Stratton, 1972 : 75-95.
Exner T., Rickard KA, Kronenberg H.Studies on phospholipids in the action of a lupus coagulation inhibitor pathology . Pathology1975; 7: 319-26.
48.
Alving BM, Baldwin PE, Richards RL et al. The dilute phospholipid APTT: a sensitive assay for verification of lupus anticoagulants. Thromb Haemostas1985; 54: 709-12.
49.
Harris EN, Gharavi AE, Boey ML et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis. Lancet1983; 2: 1211-14.
50.
DerksenRHWM, Beisma D, Bouma BN. Discordant effects of prednisone on anticardiolipin antibodies and the lupus anticoagulant. Arthritis Rheum1986; 20: 1295-6.
51.
Lockshin MD , Qamar T., Druzin M. et al. Antibody to cardiolipin, lupus anticoagulant and fetal death. J Rheumatol1987; 14: 259-62.
52.
Pierangeli SS, Krnic S., Goldsmith GH et al. Autoimmune antiphospholipid antibodies differ from syphilis antiphospholipid antibodies in their functional and binding characteristics. Blood1993; 82: 404 (abstract).
53.
Oosting JD, Derksen Rhwm, Entjes TI et al. Lupus anticoagulant activity is frequently dependent on the presence of β2 glycoprotein 1. Thromb Haemostas1992; 67: 499-502.
54.
Wei-Shi, Chang BH, Hogg PJ et al. Anticardiolipin antibodies block the inhibition by β2-glycoprotein 1 of the factor Xa generating activity of platelets. Thromb Haemostas1993 ; 70: 342-5.
55.
Sammaritano LR, Gharavi AE, Soberano C. et al. Phospholipid binding of antiphospholipid antibodies and placental anticoagulant protein . J Clin Immunol1992; 12: 27-35.
56.
Bevers EM, Galli M., Barbui T. et al. Lupus anticoagulant (LA) IgGs are not directed to phospholipids only but to a complex lipid-bound human prothrombin. Thromb Haemostas1991; 66: 629-32.
57.
Mouritsen S. , Hoier-Madsen M., Wiik A. et al. The specificity of anticardiolipin antibodies from syphilis patients and from patients with systemic lupus erythematosus . Clin Exp Immunol1989 ; 76: 178-73.
58.
Levy RA, Gharavi AE, Sammaritano LR et al. Fatty acid chain is a critical epitope for antiphospholipid antibody. J Clin Immunol1990; 10: 141-5.
